Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Current Assets: 2022-2025

Historic Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $307.7 million.

  • Centessa Pharmaceuticals' Current Assets fell 45.87% to $307.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.7 million, marking a year-over-year decrease of 45.87%. This contributed to the annual value of $536.4 million for FY2024, which is 70.24% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Current Assets stood at $307.7 million for Q3 2025, which was up 2.43% from $300.4 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Current Assets ranged from a high of $581.2 million in Q1 2022 and a low of $284.5 million during Q1 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Current Assets averaged around $371.2 million, with its median value being $347.7 million (2025).
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 70.96% in 2024, then plummeted by 45.87% in 2025.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Current Assets stood at $437.7 million in 2022, then dropped by 28.02% to $315.1 million in 2023, then skyrocketed by 70.24% to $536.4 million in 2024, then plummeted by 45.87% to $307.7 million in 2025.
  • Its Current Assets stands at $307.7 million for Q3 2025, versus $300.4 million for Q2 2025 and $347.7 million for Q1 2025.